Peptide handling
Tesamorelin reconstitution calculator
Reconstitution calculator for Tesamorelin, prefilled for its 2 and 5 mg vials. Get the concentration, the dose volume and the U-100 syringe reading.
Start from a compound
Fills the vial size and a starting water volume. Only compounds with a citable range fill a dose.
The second is the question asked once the syringe is already filled, or when checking a vial someone else reconstituted.
1 mg = 1,000 mcg. Published figures are usually micrograms; vial labels are milligrams.
- Draw to
- 200 unitson a U-100 syringe
- Dose
- 2000 mcg
- Dose volume
- 2 mL
- Concentration
- 1 mg/mL
- Per unit
- 10 mcg
- Doses per vial
- 1whole doses; a partial one is not counted
More than a 100-unit syringe holds — this needs more than one draw, or less water in the vial.
Tesamorelin — Approved label or registrational trial
Taken from an approved label or the trial it was based on. The prefilled dose is the low end of that range, daily, no titration.
Vial size and water volume are a starting point for the arithmetic, not a recommendation.
Adding more water makes the same dose a larger, easier-to-read mark on the syringe. It does not change how many doses the vial holds.
Vial sizes and starting volume
Tesamorelin is commonly supplied in 2 mg and 5 mg vials. The calculator opens on a 2 mg vial with 2 mL of bacteriostatic water — a starting point for the arithmetic, not a recommendation. Change either and everything recalculates.
That combination gives 1 mg/mL, so one insulin unit holds 10 mcg and a 2000 mcg dose is 200 units.
What dose to enter
A range of 2000–2000 mcg per dose can be cited for Tesamorelin, daily, no titration. The dose field opens at the low end of it.
Approved label or registrational trial
Taken from an approved label or the trial it was based on.
- Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in HIV-infected patients with excess abdominal fat: pooled analysis of two randomized trials. — Pooled phase III analysis. Pooled phase III trial data behind the approved 2 mg daily dose.
- Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial. — Human randomized controlled trial. Randomized human trial at the same approved 2 mg dose, for a secondary indication.
- LiverTox: Tesamorelin. — Drug safety reference. NIH drug-safety reference confirming the approved product and its labeled dose.
- Tesamorelin Effects on Liver Fat and Histology in HIV (NCT02196831). — ClinicalTrials.gov registry. Registered human trial at the approved dose, studying liver fat and histology.
- Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors. — Human clinical study. Further human efficacy and safety data at the approved dose in a modern treatment context.
Related
- Tesamorelin — the product page, with its current batch.
- Bacteriostatic water — what goes in the vial.
- Peptide reconstitution calculator — the general version, with the blend and half-life calculators alongside it.
- Dosing reference — published schedules, each with the evidence behind it.
For research use only. This tool performs arithmetic on figures you supply — it is not medical guidance and does not recommend a dose for any compound.